Higher mortality rates associated with rheumatoid arthritis in Saskatchewan,Canada, 2001–2019

ObjectivesTo estimate provincial all-cause mortality rates of Saskatchewan people with rheumatoid arthritis (RA) for comparison with the general population over time and between different geographic regions.MethodsSaskatchewan provincial administrative health databases (2001–2019) were utilized as data sources. Two RA case definitions were employed: (1) ≥ 3 physician billing diagnoses, at least 1 from a specialist (rheumatologist, general internist or orthopaedic surgeon) within 2 years; (2) ≥ 1 hospitalization diagnosis (ICD-9 code 714, and ICD-10-CA codes M05, M06). Data from these definitions were combined to create an administrative data RA cohort. All-cause mortality rates across geographic regions, between rural/urban residences and between sexes were examined.ResultsOver an 18-year span, between fiscal-year 2001–2002 and fiscal-year 2018–2019, age- and sex-adjusted mortality rates ranged from 17.10 to 21.04 (95% CI 14.77, 19.44; 18.03, 24.05)/1000 RA person-years, compared with mortality rates for the general Saskatchewan population without RA, which ranged from 9.37 to 10.88 (95% CI 9.23, 9.51; 10.72, 11.05)/1000 person-years. Fiscal-year mortality rate ratios ranged from 1.82 to 2.13 (95% CI 1.56, 2.13; 1.83, 2.46). Provincial mortality rates were higher in men than in women for both general and RA populations. Northern Saskatchewan mortality rates were significantly higher in the general population but did not achieve significance compared with other provincial regions for the RA population. Regression analysis identified age, male sex, RA and geographic region as factors contributing to increased mortality. A trend towards lower mortality rates over time was observed.ConclusionHigher mortality rates were observed in the RA population overall. Men had higher mortality rates, as did residents of Northern Saskatchewan compared with residents of other regions for the general population.     

我国女性性工作者领域社会组织参与艾滋病防治项目管理能力建设需求研究

目的 了解为女性性工作者（FSW）提供艾滋病防治服务的社会组织项目管理能力建设需求。方法 向2017-2018年参与国家艾滋病防治基金项目的社会组织负责人开展问卷调查及访谈,结合基金项目管理信息系统相关数据,利用Excel 2016软件和SPSS 25.0软件整理分析社会组织的分布与基金获得情况,以及社会组织对项目管理能力的需求。结果 2017-2018年参与执行基金FSW项目的社会组织共184个,完成问卷调查的社会组织156个,主要集中在西部地区（44.0%,81/184）,以四川省、广西壮族自治区和云南省居多;东部地区获得的基金支持最多;社会组织对项目数据收集及分析利用的需求最高,占68.6%（107/156）,其次是项目风险分析应对及质控,占64.1%（100/156）;社会组织负责人学历对项目计划管理和项目财务管理能力建设需求的差异有统计学意义（χ²=5.78,P=0.016;χ²=8.99,P=0.003）。结论 当前我国FSW领域的社会组织数量和基金获得比例的分布,与异性性传播的艾滋病疫情分布不一致。仍需继续鼓励、引导扶持社会组织的发展资金;结合社会组织对能力建设的需求针对性的制定项目能力建设计划。     

苏州市儿童BMI-Z变化轨迹与青春晚期血压偏高的关联研究

目的 探讨年龄和性别标准化BMI-Z值（BMI-Z）轨迹与青春晚期（16~18岁）血压偏高的关系。方法 基于苏州市儿童和青少年健康监测项目（HPPCA）2012-2019年的数据,以2019年的监测数据为结局,将末次监测年龄为16~18岁且总监测次数≥4的11 812名儿童青少年纳入研究。运用潜变量生长混合模型分析不同性别儿童成长过程中的BMI动态变化（BMI-Z变化轨迹）,采用多因素logistic回归分析BMI动态变化与青春晚期血压偏高的关系。结果 在男、女生中各确定了6条BMI-Z变化轨迹,分别为较瘦组、略瘦组、标准组、下降组、超重组和肥胖组。与标准组相比,男生肥胖组在青春晚期发生血压偏高的风险增加94.0%（OR=1.94,95%CI：1.43~2.63）,而女生肥胖组则增加107.0%（OR=2.07,95%CI：1.33~3.22）。男女生中下降组与青春晚期血压偏高发病均没有显著关联。结论 儿童持续性肥胖会增加青春晚期罹患血压偏高的风险;若对肥胖儿童及时采取干预措施,使其在青春晚期恢复正常体重,或许能降低血压偏高的风险。     

中国国家出生队列研究质量控制策略与措施

出生队列是研究孕前和孕期各种环境暴露因素与胎儿、婴幼儿、青少年健康之间关系的有效方法。出生队列建设周期长、环节众多,研究质量可能受到多种因素的影响。本文对中国国家出生队列建设过程中的各项质量保证和质量控制措施进行梳理,归纳总结建设经验。以期为相关队列研究提供经验,减少相关因素对队列研究的影响,提升队列研究质量。中国国家出生队列在质量保证的顶层设计方面采取一系列措施保障研究质量,包括研究中心筛选、成员管理系统开发、标准化操作流程制定及工作人员规范化培训;在质量控制方面,包括针对队列数据产生过程的实时、及时、定时质控,针对生物样本采集、处理及保存的全周期质控,以及针对参与工作人员的培训、督查和量化考核的全面立体质控。     

中国国家出生队列研究调查对象的基线特征分析

目的 探讨生命早期环境因素、遗传因素和遗传与环境交互作用对子代近期和远期健康的影响以及系统评价和比较辅助生殖受孕和自然受孕人群的妊娠结局和子代健康相关结局。方法 中国国家出生队列（CNBC）研究是一项覆盖辅助生殖受孕家庭和自然受孕家庭的多中心前瞻性出生队列研究。2016年,CNBC项目陆续在我国12个省（自治区、直辖市）的24所医院启动,以家庭为单位纳入研究对象,并在辅助生殖治疗前、胚胎移植、孕早期、孕中期、孕晚期及分娩时以及出生后第42天、6个月、12个月、36个月多个时点采集数据信息和生物样本。结果 截至2020年6月,CNBC共纳入27 044个辅助生殖受孕家庭,29 589个自然受孕家庭,CNBC的研究人群中绝大部分为城市居民。在辅助生殖受孕家庭中,男女双方分别有65.5%和63.7%为大学及以上文化程度,年龄为（33.83±5.52）和（32.38±4.67）岁;女方83.2%为初产妇,吸烟率为0.8%,饮酒率为2.1%。在自然受孕家庭中,男女双方分别有81.5%和86.5%为大学及以上文化程度,年龄为（32.06±5.09）和（30.40±4.27）岁,女方67.2%为初产妇,吸烟率为0.1%,饮酒率为2.2%。不同地区的辅助生殖受孕家庭和自然受孕家庭的基线特征均有差异。结论 CNBC的建立将为研究生命早期遗传、环境因素、遗传-环境交互作用以及辅助生殖技术治疗相关因素对出生后子代健康的影响提供了重要资源。     

The establishment of the Korean medical device safety information monitoring center: Reviewing ten years of experience

Medical devices may revolutionize healthcare delivery but can lead to serious adverse events for treated patients and users. While reporting of adverse events related to medical devices is an essential starting point for post-market surveillance, underreporting of medical device adverse events is a global problem. Korea introduced a voluntary medical device adverse event reporting system in 2010, called the Medical Device Safety Information Monitoring Center, which has led to an increase in adverse event reports. For 10 years, the Medical Device Safety Information Monitoring Center has analyzed medical device adverse events systematically and has provided active feedback to the manufacturers and education on safe use. Recently, the Medical Device Safety Information Monitoring Center contributed to harmonization of international medical device vigilance through the sharing of adverse events. This experience of Korea might contribute to improvements in medical device vigilance, which is a critical prerequisite for improving medical device policies and regulations.     

Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in rhesus macaques

Zika virus (ZIKV) infection has caused major public health problems recently. To develop subunit vaccines for ZIKV, we have previously constructed recombinant ZIKV envelope protein domain III (EDIII), and the entire ectodomain (E80, which comprises EDI, EDII and EDIII), as vaccine candidates and showed both of them being immunogenic and protective in murine models. In this follow-up study, we compared these vaccine candidates in non-human primates. Both of them elicited neutralizing antibody responses, but only E80 immunization inhibited ZIKV infection in both peripheral blood and monkey tissues, whereas EDIII increased blood ZIKV RNA through possibly antibody-dependent enhancement. Further investigations revealed that the virion-binding antibody response in E80 immunized monkeys persisted longer and stronger than in EDIII immunized monkeys. These results demonstrate that E80 is superior to EDIII as a vaccine candidate, and that the magnitude, quality and durability of virion-binding neutralizing antibodies are correlates of protection.     

The prevalence of stroke and related risk factors among residents aged ≥ 40 years in Chongqing,Southwest China

Journal of Public Health - China bears the largest global stroke burden, yet little is known about its rates in Chongqing, southwest China. We aimed to investigate the prevalence and related risk...     

1例肺移植的干燥综合征患者联用奈玛特韦/利托那韦与环孢素、他克莫司导致肾功能损伤

1例76岁右单肺移植的干燥综合征男性患者在新冠病毒感染后使用奈玛特韦/利托那韦治疗,导致合并使用的免疫抑制剂环孢素和他克莫司全血药物谷浓度升高,引起血肌酐升高,后通过停用环孢素、调整他克莫司剂量使他克莫司浓度维持在治疗浓度,血肌酐水平较前改善,患者好转出院。此病例可为临床安全用药实践提供参考。     

复合纳米人工骨的注射、凝固及其机械性能研究

目的 构建半水硫酸钙和纳米羟基磷灰石为主的复合人工骨材料并对其注射性能、凝固性能和机械强度的影响因素进行考察.方法 测试不同液固比条件下复合材料的注射特性,25℃和37℃时分别测试不同液固比、不同二水硫酸钙促凝剂条件下的材料初、终凝时间和压缩强度,均与纯硫酸钙作对比.结果 液固比0.50以上时注射性能满意.无论何种液/固比,复合材料的凝固时间均较硫酸钙延长,37℃下的凝固时间较25℃下延长.一定范围内促凝剂用量过大或过小均使凝固时间延长.液固比越大或促凝剂用量越高,材料压缩强度越低.纳米磷灰石含量增大则材料强度降低.结论 合理掌握纳米磷灰石的比例,液固比和促凝剂的用量,是开发可注射纳米人工骨的关键.